CytomX Therapeutics, Inc.
CTMX
$2.98
$0.041.36%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.54M | 76.20M | 113.63M | 141.10M | 147.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.54M | 76.20M | 113.63M | 141.10M | 147.56M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 35.54M | 76.20M | 113.63M | 141.10M | 147.56M |
| SG&A Expenses | 30.00M | 28.74M | 28.10M | 29.63M | 31.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.40M | 95.77M | 90.39M | 97.98M | 111.60M |
| Operating Income | -61.86M | -19.57M | 23.25M | 43.13M | 35.96M |
| Income Before Tax | -58.91M | -17.13M | 28.26M | 48.23M | 41.84M |
| Income Tax Expenses | 234.00K | 237.00K | 245.00K | 248.00K | 236.00K |
| Earnings from Continuing Operations | -59.14 | -17.37 | 28.02 | 47.98 | 41.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.14M | -17.37M | 28.02M | 47.98M | 41.60M |
| EBIT | -61.86M | -19.57M | 23.25M | 43.13M | 35.96M |
| EBITDA | -60.62M | -18.19M | 24.53M | 44.70M | 37.65M |
| EPS Basic | -0.36 | 0.01 | 0.40 | 0.56 | 0.48 |
| Normalized Basic EPS | -0.21 | 0.03 | 0.25 | 0.35 | 0.30 |
| EPS Diluted | -0.37 | 0.00 | 0.40 | 0.56 | 0.48 |
| Normalized Diluted EPS | -0.21 | 0.03 | 0.25 | 0.35 | 0.30 |
| Average Basic Shares Outstanding | 641.04M | 550.89M | 466.94M | 387.03M | 342.84M |
| Average Diluted Shares Outstanding | 641.04M | 550.92M | 466.97M | 387.17M | 342.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |